Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition

Author： Bush H.S.  

Publisher： Elsevier

ISSN： 0736-4679

Source： Journal of Emergency Medicine, Vol.25, Iss.4, 2003-11, pp. : 421-426

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 34, Iss. 5, 2016-10 ,pp. : 330-336

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intracoronary GP IIb/IIIa Inhibitors: Could Eptifibatide Be the New Kid on the Block?

By  

Cardiology, Vol. 123, Iss. 1, 2012-09 ,pp. : 43-45

Karger

Access to resources Recommend Favorite

Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 3, 2004-11 ,pp. : 27-43

Karger

Access to resources Recommend Favorite

A Quick Simple Method of Determining Platelet Aggregability following Glycoprotein IIb/IIIa Receptor Inhibitor Administration

By  

Cardiology, Vol. 91, Iss. 3, 1999-09 ,pp. : 156-160

Karger

Access to resources Recommend Favorite

Effects of Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban on Minor Myocardial Damage in Angiographically Successful Percutaneous Coronary Angioplasty

By  

Cardiology, Vol. 102, Iss. 1, 2004-04 ,pp. : 18-23

Karger

Access to resources Recommend Favorite